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Abstract
Clinical trials in specific indications require the administration of
rescue medication in case a patient does not sufficiently respond to in-
vestigational treatment. The application of additional treatment on an
as needed basis causes problems to the analysis and interpretation of
the results of these studies since the effect of the investigational treat-
ment can be confounded by the additional medication. Following-up
all patients until study end and capturing all data is not fully address-
ing the issue. We present an analysis that takes care of the fact that
rescue is a study outcome and not a covariate when rescue medication
is administered according to a deterministic rule. This approach allows
to clearly define a biological effect. For normally distributed longitudi-
nal data a practically unbiased estimator of the biological effect can be
obtained. The results are compared to an ITT analysis and an analysis
on all patients not receiving rescue.
Keywords: rescue medication, potential outcomes, principal strata, biologi-
cal effect.
1 Introduction
In clinical trials in specific indications it is necessary to provide patients the
opportunity to receive an established medication, either alone or in combi-
nation with study treatment, in case of insufficient response. This additional
treatment is called rescue medication, or sometimes reliever medication. In
diabetes trials patients are to receive rescue medication in case blood glu-
cose does not decrease over time (see for example [1]). In trials in chronic
obstructive pulmonary disease (COPD) [2, 3] rescue may be given to prevent
exacerbations.
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The rules according to which the need for rescue medication is deter-
mined varies between indications. For diabetes trials, these rules are often
precisely defined. For example study [1] required open-label piaglitazone or
acarbose for fasting plasma glucose concentrations above 15 mmol/L (week
4–8), 13.3 mmol/L (week 8–12) or 11.1 mmol/L (week 12–24). For res-
cued patients, measurements obtained after initiation of rescue medication
were excluded from the efficacy analysis which consisted of an analysis of
covariance with last observation carried forward for missing data.
In COPD trials, the patient determines the need for rescue medication
and applies it himself. Since short acting medication is used, the impact on
the results of the study outcome is considered minimal as long as rescue is
not taken on the day of an assessment. The primary analysis of the main
endpoint, change of forced expiratory volume within one second (FEV1), is
an ITT-analysis including all patients irrespectively of rescue medication.
The frequency and amount of the latter is usually analyzed as a secondary
endpoint to support the results of the primary analysis [2, 3].
In general, the application of additional treatment not delivered accord-
ing to random assignment but for a treatment emergent reason causes prob-
lems for analysis and interpretation of the results. Allowing or requesting
rescue medication confounds the effect of the treatment under investigation.
The administration of rescue medication is strictly speaking a study out-
come, not a covariate, which in turn may have an impact on the observed
outcome.
Recent literature encourages to follow-up all randomized subjects even if
they alter the randomly assigned treatment [4]. This is not a principal prob-
lem for patients receiving rescue. However, it is not a priori clear whether
and how to use the data obtained after rescue in a meaningful way in the
statistical analysis of the trial (see [5, 6]).
One approach to analyze data from trials calling for rescue is a strict ITT
analysis, i.e., an analysis that considers only the assigned treatment and ig-
nores the administration of rescue. This can be sensible approach when
rescue is needed by the majority of patients at some point in time during
the trial but is applied only for a short amount of time without interrup-
tion of the treatment under investiagtion. By following this principle one
preserves the benefit of randomization in creating groups that do not differ
systematically on any factors except those assigned in an trial. However,
such an analysis would estimate the effect of assigning control or treatment,
but not necessarily the biological effect of the latter over the former. If the
biological effect of the investigational treatment alone is of interest, the ITT
analysis is not appropriate [7, 8].
One could also consider data after rescue as missing and impute them
by carrying the last observation forward (as in [1]) or by a more appropri-
ate procedure (see [4]). However, it is not obvious which effect would be
estimated by such an analysis.
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The notion of a per protocol analysis is not straightforward in the context
of rescue medication. When rescue is administered according to protocol,
receiving rescue would not constitute a protocol deviation and the respec-
tive patients would still be part of the per-protocol set. Alternatively one
could compare only data from patients that did not receive rescue medi-
cation. However, such an analysis would consider observations that have
been selected according to their response to different treatments. Since this
analysis would not compare like with like, the biological effect can also not
be estimated appropriately in this way [7, 8]. For a quantitative account of
the impact of rescue on standard analyses see White et. al [9].
Eventually one could also interpret administration of rescue medication
as treatment failure and compare the number of patients that need rescue
medication (or likewise the time to rescue medication) or the amount of
rescue taken. However such an analysis does not provide an estimate of an
effect on the primary outcomes of the study and may therefore be best used
as a supportive analysis (like in COPD trials).
A different way to think about how to obtain an estimate of the biologi-
cal effect is by considering potential outcomes [10] and principal strata [11].
These notions have been introduced to investigate the impact of non-compliance
to assigned treatment. The key idea is to stratify on an intermediate out-
come, in our case the administration of rescue. However, patients are not
stratified according to the observed administration of rescue, which is an
outcome affected by the treatment assigned at baseline. Rather they are
classified according to whether they would (or would not) need rescue under
investigational treatment or control.
In the context of rescue medication, one can consider four strata of pa-
tients: those who do not need rescue regardless of assigned treatment (ab-
breviated 00), those who need rescue when assigned control but not when
assigned treatment (10), those who need rescue when assigned treatment
but not when assigned control (01) and those in need of rescue no matter
how treated (11). If control treatment is a placebo, one may argue that stra-
tum (01) is empty since patients not responding to investigational treatment
are not responding to placebo either since the former is a placebo as well.
This approach has been applied under a likelihood [12] as well as a Bayesian
paradigm [13] to obtain estimates for the biological effect in subjects that
do not fail under either treatment option (stratum 00). However, univari-
ate methods were considered that would necessitate to define a summary
outcome for studies with repeated measures.
We consider a simple longitudinal setting consisting of 2 visits only and
an explicit (deterministic) rule for the administration of rescue. The rule
basically states that if the values at an earlier visit are lower or higher than
acceptable, the subject should receive rescue medication. The endpoint
to assess an effect of the investigational treatment will be captured at the
final (second) visit of the trial. The only stratum that provides an non-
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confounded estimator of the treatment effect is patients that do not need
rescue under treatment nor control (00). Under plausible distributional
assumptions, the biological effect of treatment over control in the 00 stratum
can be estimated without having to use computationally intensive methods
like EM algorithms or Markov Chain Monte Carlo techniques.
After introducing notation and concept of potential outcomes and their
relationship to observations, a practically unbiased estimator of the biologi-
cal effect of interest is presented. Its small sample properties are investigated
by simulation. Some questions for further investigations are discussed.
2 Observations and potential outcomes
We consider a parallel group trial where experimental treatment (Z = 1)
is to be compared with control (Z = 0) treatment. The treatment is to be
randomly assigned to 1 ≤ i ≤ nj, (j = 0, 1) patients who provide obser-
vations (Yi1, Yi2) from two visits. For the discussion we assume that high
values are beneficial and low values indicate lack of efficacy. The rule for
applying rescue is that if the observed values are too small at the first visit
after treatment initiation, i.e., Yi1 ≤ c for some predefined critical value c,
the subject has to receive rescue medication, denoted by Ri = 1. Ri = 0
means that no rescue is necessary. As a consequence, the outcome at the
second visit will be affected not only by the treatment assigned at baseline,
but also by the rescue medication administered after the first visit. Not
to complicate matters further, we assume complete data at each visit, i.e.,
(Yi1, Yi2) are observed for all patients and investigators and patients adhere
to the rules for administration of rescue medication.
In the following we use the notion of potential outcomes. We drop the
index accounting for the subject number whenever possible to ease notation.
Let Y1(z) be the potential outcome of a subject at visit 1 had treatment z
been assigned at baseline. Let R(z) denote the potential rescue medication of
a subject assigned to treatment z. Likewise, let Y2(z, r) denote the potential
outcome of a subject at visit 2 assigned treatment z at baseline and having
received rescue medication r at visit 1. The biological effect of treatment
z on the outcomes at visit 1 is given by E1 = E[Y1(1)] − E[Y1(0)], and
the biological effect of treatment z at visit 2 in stratum (i, j) is E2(i, j) =
E[Y2(1, i)] − E[Y2(0, j)]. Specifically in the stratum of subjects who do not
need rescue under either treatment it is E2(0, 0) = E[Y2(1, 0)]−E[Y2(0, 0)].
An artificial example is displayed in Table 1.
The left column shows the percentage of patients in the sample belonging
to the respective principal strata. The causal effects for the respective strata
are provided in the rightmost column. Of course, in reality, these proportions
and the respective strata means are not observable. There is a benefit for
patients in all but one principal stratum from receiving treatment making
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% Principal Control Treatment Effect
stratum R(0) E[Y (0, R(0))] R(1) E[Y2(1, R(1))]
60 00 0 0 0 1 1
10 01 0 0 1 3 3
10 10 1 1 0 1 0
20 11 1 1 1 3 2
Table 1: Example of expected outcomes in principal strata for a trial requir-
ing rescue medication
treatment beneficial for 80% of subjects. The ITT effect is 0.6 × 1 + 0.1 ×
3 + 0.2 × 2 = 1.3 while the effect in patients not requiring rescue is 1.
To obtain estimates of the biological effect E2(0, 0), a connection between
the potential outcomes and the observations Y1, Y2, R has to be established.
Obviously,
Y1 = ZY1(1) + (1− Z)Y1(0)
R = ZR(1) + (1− Z)R(0)
Y2 = ZY2(1, R(1)) + (1− Z)Y2(0, R(0))
Y1Y2 = ZY1(1)Y2(1, R(1)) + (1− Z)Y1(0)Y2(0, R(0))
The last equation follows from Z(1−Z) = 0, Z2 = Z and (1−Z)2 = 1−Z.
Under the assumption that Z is assigned randomly to subjects, Y1(z) and
R(z) are independent of Z and therefore
E[Y1|Z = z] = E[Y1(z)]
E[R|Z = z] = E[R(z)].
This can be seen for R from
E[R|Z = 1] = E[ZR(1) + (1− Z)R(0)|Z = 1] = E[R(1)|Z = 1] = E[R(1)].
As a result, the conditional expectation of the observations Y1 and R given
Z = z equals the expectation of their respective counterfactual outcomes.
This is no longer true for Y2, since Y2 is confounded by R. In fact
E[Y2|Z = 1, R = 0]
= E[ZY2(1, R(1)) + (1− Z)Y2(0, R(0))|Z = 1, R = 0]
= E[Y2(1, R(1))|Z = 1, R = 0]
= E[Y2(1, R(1))|R(1) = 0]
= E[Y2(1, 0)|R(1) = 0]
= E[Y2(1, 0)|Y1(1) > c]
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Similarly one can show E[Y2|Z = 0, R = 0] = E[Y2(0, 0)|Y1(1) > c], and
therefore
E[Y2|Z = z,R = 0] = E[Y2(z, 0)|Y1(z) > c] (1)
confirming that an estimator of E[Y2|Z = z,R = 0] is not appropriate as an
estimator of E[Y2(z, 0)].
3 A biological effect estimator
To obtain an estimator of E[Y2(z, 0)] from E[Y2|Z = z,R = 0], a correction
is necessary. It is shown in this section that such a correction can be ob-
tained for normally distributed variables. Assume that (Y1(z), Y2(z, r)) has
a bivariate normal distribution with means
µ1(z) = E[Y1(z)] = α1 + β1z
µ2(z, r) = E[Y2(z, r)] = α2 + β2z + γr + δzr
and covariance matrix
Σ(z, r) =
(
σ211(z) σ12(z, r)
σ12(z, r) σ
2
22(z, r)
)
It should be noted that the decision on rescue at visit 1 can be based on an
endpoint different from the one on which the efficacy assessment is based on
at visit 2.
Under the model above, β2 = µ2(1, 0) − µ2(0, 0) is the causal effect of
z at visit 2 in the principal stratum of subjects that do not require rescue
under any assigned treatment. Let γ12(z, r) = σ12(z, r)σ
−2
11 (z) and recall
that for bivariate normal variables
E[Y2(z, r)|Y1(z)] = µ2(z, r) + γ12(z, r){Y1(z)− µ1(z)}
holds. Let φ, Φ, and λ denote the pdf, cdf and hazard function of a standard
normal variable, respectively. With η(z) = [c−µ1(z)]/σ11(z), it follows that
E[Y1(z)|Y1(z) > c] = µ1(z) + σ11(z)φ(η(z))[1 − Φ(η(z))]
−1
= µ1(z) + σ11(z)λ(η(z))
Then
E[Y2(z, 0)|Y1(z) > c]
= E[E[Y2(z, 0)|Y1(z)]|Y1(z) > c]
= E[µ2(z, 0) + γ12(z, 0){Y1(z)− µ1(z)}|Y1(z) > c]
= µ2(z, 0) + γ12(z, 0){E[Y1(z)|Y1(z) > c]− µ1(z)}
= µ2(z, 0) + γ12(z, 0)σ11(z)λ(η(z)) (2)
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Estimator of β2
α1 β1 α2 β2 γ δ ITT Conditional Corrected
1 0 0 0 0 0 0.001 (0.201) 0.001 (0.200) 0.001 (0.200)
0 1 0 0 0 0 -.003 (0.195) -.226 (0.205) -.003 (0.205)
0 0 1 0 0 0 -.002 (0.205) -.001 (0.221) -.001 (0.221)
0 0 0 1 0 0 1.001 (0.201) 1.000 (0.220) 1.000 (0.220)
0 0 0 0 1 0 0.001 (0.179) 0.001 (0.219) 0.001 (0.219)
0 0 0 0 0 1 0.308 (0.191) -.002 (0.219) -.002 (0.219)
0 0 0 0 1 1 0.307 (0.192) -.000 (0.219) -.000 (0.219)
0 1 0 1 0 0 1.003 (0.199) 0.781 (0.209) 1.003 (0.209)
0 1 0 1 1 0 0.759 (0.183) 0.777 (0.208) 0.999 (0.208)
0 1 0 1 1 1 0.825 (0.187) 0.779 (0.209) 1.001 (0.209)
0 0 0 1 1 1 1.309 (0.190) 0.999 (0.218) 0.999 (0.218)
Table 2: Means and standard deviations of the estimates of the effect of
treatment at visit 2 from an ITT analysis, an estimator of E[Y2|Z = 1, R =
0] − E[Y2|Z = 0, R = 0] and the corrected estimator (3) for n0 = n1 = 50,
σ11(z) = σ22(z) = 1, σ12(z, r) = 0.6 and c = −0.5 from 10000 simulations
From equations (1) and (2) one obtains
µ2(z, 0) = E[Y2|Z = z,R = 0]− γ12(z, 0)σ11(z)λ(η(z)). (3)
The conditional expectation of the observed value equals the expectation
of the potential outcome if σ12(z, 0) = 0, in which case observations from
different visits are independent and the probability of rescue medication
depends only on the randomly assigned treatment z and is thus independent
of the potential outcome. In this case, the causal effect β2 equals E[Y2|Z =
1, R = 0]−E[Y2|Z = 0, R = 0]. The latter is also the case if σ12(z, 0)λ(η(z))
does not depend on the assigned treatment z which is a somewhat artificial
condition.
To appreciate the discrepancies between different estimators of a treat-
ment effect of z in the absence of rescue, Table 2 presents the effect estimator
from an ITT analysis, an estimator of E[Y2|Z = 1, R = 0]−E[Y2|Z = 0, R =
0] and the estimator corrected according to (3). The entries are obtained
from 10000 simulations per row. Only the corrected estimator is estimating
the causal effect β2 appropriately.
To make the correction practically useful, the parameters it comprises
need to be estimated from the data. Most of them are indeed estimable
from observations at visit 1 with the exception of σ12(z, 0). With
E[Y 21 (z)|Y1(z) > c] = µ
2
1(z) + σ11(z){σ11(z) + [c+ µ1(z)]λ(η(z))}
one obtains using similar arguments as in the previous section
E[Y1Y2|Z = z,R = 0]
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α1 β1 α2 β2 γ δ βˆ2 σˆ12(0) σˆ12(1)
1 0 0 0 0 0 0.001 (0.215) 0.592 (0.149) 0.591 (0.151)
0 1 0 0 0 0 -.006 (0.252) 0.596 (0.228) 0.591 (0.149)
0 0 1 0 0 0 -.003 (0.289) 0.560 (0.279) 0.561 (0.273)
0 0 0 1 0 0 1.019 (0.297) 0.597 (0.229) 0.555 (0.282)
0 0 0 0 1 0 0.002 (0.301) 0.597 (0.229) 0.596 (0.226)
0 0 0 0 0 1 -.005 (0.299) 0.594 (0.228) 0.597 (0.226)
0 0 0 0 1 1 0.002 (0.300) 0.596 (0.227) 0.592 (0.229)
0 1 0 1 0 0 1.002 (0.257) 0.596 (0.226) 0.588 (0.136)
0 1 0 1 1 0 0.997 (0.257) 0.595 (0.227) 0.584 (0.140)
0 1 0 1 1 1 1.001 (0.259) 0.599 (0.226) 0.586 (0.138)
0 0 0 1 1 1 1.017 (0.292) 0.597 (0.227) 0.557 (0.279)
Table 3: Means and standard deviations of the estimates of the effect of
treatment at visit 2 and the correlation of Y1(z) and Y2(z, 0) for n0 = n1 =
50, σ11(z) = σ22(z) = 1, σ12(z, r) = 0.6 and c = −0.5 from 10000 simulations
= E[Y1(z)Y2(z, 0)|Y1(z) > c]
= E[Y1(z)E[Y2(z, 0)|Y1(z)]|Y1(z) > c]
= E[Y1(z){µ2(z, 0) + γ12(z, 0)(Y1(z)− µ1(z))}|Y1(z) > c]
= {µ2(z, 0) − γ12(z, 0)µ1(z)}E[Y1(z)|Y1(z) > c]
+ γ12(z, 0)E[Y
2
1 (z)|Y1(z) > c]
= [µ2(z, 0) − γ12(z, 0)µ1(z)][µ1(z) + σ11(z)λ(η(z))]
+ γ12(z, 0){µ
2
1(z) + σ11(z)[σ11(z) + (c+ µ1(z))λ(η(z))]}
= µ2(z, 0)[µ1(z) + σ11(z)λ(η(z))] + γ12(z, 0)σ11[σ11(z) + cλ(η(z))].
Substituting µ2(z, 0) from equation (3) yields
σ12(z, 0) =
E[Y1Y2|Z = z,R = 0]− E[Y2|Z = z,R = 0][µ1(z) + σ11(z)λ(η(z))]
1 + λ(η(z))[η(z) − λ(η(z))]
(4)
The parameters on the right hand side of (4) are consistently estimable from
the data, hence a consistent estimator of σ12(z, 0) can be obtained. Data
from all patients are used for estimating µ(z), σ11 and λ(η(z)). Only data
from patients that did not require rescue medication during the trial are
used for E[Y1Y2|Z = z,R = 0] and E[Y2|Z = z,R = 0].
We run a small simulation study to get an idea of the performance of
a plug-in estimator obtained by replacing the parameters on the right-hand
side of the preceding equation by their estimates. The results are displayed
in Table 3. As can be seen, the proposed estimate works quite well in the
given scenario, however, there seems to be a tendency to underestimate the
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covariance in particular when the proportion of rescue is increasing. When
we re-run the simulation with a higher sample size of 500 in each treatment
group this phenomenon practically disappeared. In any case this suggests
that the estimate may become inaccurate for small sample sizes.
4 Discussion
An estimator of the biological effect of an investigational treatment over
control has been proposed for clinical trials where patients are administered
rescue medication if the assigned treatment fails. The main assumptions
are a bivariate normal model for the potential outcomes at visits 1 and 2,
and a deterministic rule for administration of rescue medication based on
observations obtained at visit 1. It should be noted that the decision on
rescue at visit 1 can be based on an endpoint different from the one on
which the efficacy assessment is based on at visit 2. A generalization to
more visits should be feasible.
When estimating the biological effect at visit 2, data from all subjects
from visit 1 are used in the analysis. However, for visit 2, only observations
from subjects without rescue medication are analyzed. The smaller effec-
tive sample size results in a somewhat larger variability of the estimate as
compared to the ITT estimate which uses the information of the full sam-
ple. However, though the latter is using more data, it is not an appropriate
biological effect estimator from an accuracy perspective.
As a recommendation for the analysis of clinical trials requiring rescue
medication one should conduct an ITT analysis to obtain an estimator of
treatment effectiveness, an analysis of the amount and/or timing of rescue
medication, and an analysis of the biological effect. If an investigational
treatment plus rescue has no or little advantage over control plus rescue,
one may wonder what could constitute an additional benefit of the new
treatment. Likewise, the efficacy of the investigational treatment is ques-
tionable if more rescue is taken there as compared to control. Nevertheless
in such a case investigational treatment may still do better than control in
patients that would not need rescue under either treatment. To figure that
out, an estimate of the biological effect would be helpful. In short there is
not one analysis that covers all aspects of the issue. An analysis based on
subjects that did not need rescue in there respective groups without any
correction is discouraged.
The standard error of the biological estimates can be obtained by re-
sampling. More importantly the smaller sample size in principal stratum
00 has to be taken into consideration during the planning phase of a trial.
Furthermore, we did not account for missing data in this paper but rather
assumed that all data needed to obtain estimates of biological effects are
available.
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